181 related articles for article (PubMed ID: 31420544)
1. Expression of CD20 after viral reactivation renders HIV-reservoir cells susceptible to Rituximab.
Serra-Peinado C; Grau-Expósito J; Luque-Ballesteros L; Astorga-Gamaza A; Navarro J; Gallego-Rodriguez J; Martin M; Curran A; Burgos J; Ribera E; Raventós B; Willekens R; Torrella A; Planas B; Badía R; Garcia F; Castellví J; Genescà M; Falcó V; Buzon MJ
Nat Commun; 2019 Aug; 10(1):3705. PubMed ID: 31420544
[TBL] [Abstract][Full Text] [Related]
2. A Novel Single-Cell FISH-Flow Assay Identifies Effector Memory CD4
Grau-Expósito J; Serra-Peinado C; Miguel L; Navarro J; Curran A; Burgos J; Ocaña I; Ribera E; Torrella A; Planas B; Badía R; Castellví J; Falcó V; Crespo M; Buzon MJ
mBio; 2017 Jul; 8(4):. PubMed ID: 28698276
[TBL] [Abstract][Full Text] [Related]
3. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
4. Select host restriction factors are associated with HIV persistence during antiretroviral therapy.
Abdel-Mohsen M; Wang C; Strain MC; Lada SM; Deng X; Cockerham LR; Pilcher CD; Hecht FM; Liegler T; Richman DD; Deeks SG; Pillai SK
AIDS; 2015 Feb; 29(4):411-20. PubMed ID: 25602681
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc Is Associated with Latent HIV-1 Reactivation through NF-κB Activation in Resting CD4
Madrid-Elena N; García-Bermejo ML; Serrano-Villar S; Díaz-de Santiago A; Sastre B; Gutiérrez C; Dronda F; Coronel Díaz M; Domínguez E; López-Huertas MR; Hernández-Novoa B; Moreno S
J Virol; 2018 May; 92(9):. PubMed ID: 29444937
[TBL] [Abstract][Full Text] [Related]
6. HIV-1-Specific Chimeric Antigen Receptor T Cells Fail To Recognize and Eliminate the Follicular Dendritic Cell HIV Reservoir
Ollerton MT; Berger EA; Connick E; Burton GF
J Virol; 2020 May; 94(10):. PubMed ID: 32161179
[TBL] [Abstract][Full Text] [Related]
7. Antigen Production After Latency Reversal and Expression of Inhibitory Receptors in CD8+ T Cells Limit the Killing of HIV-1 Reactivated Cells.
Ruiz A; Blanch-Lombarte O; Jimenez-Moyano E; Ouchi D; Mothe B; Peña R; Galvez C; Genescà M; Martinez-Picado J; Goulder P; Barnard R; Howell B; Clotet B; Prado JG
Front Immunol; 2018; 9():3162. PubMed ID: 30723480
[TBL] [Abstract][Full Text] [Related]
8. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.
Offersen R; Nissen SK; Rasmussen TA; Østergaard L; Denton PW; Søgaard OS; Tolstrup M
J Virol; 2016 May; 90(9):4441-4453. PubMed ID: 26889036
[TBL] [Abstract][Full Text] [Related]
9. Reduction of the HIV-1-infected T-cell reservoir by immune activation treatment is dose-dependent and restricted by the potency of antiretroviral drugs.
Fraser C; Ferguson NM; Ghani AC; Prins JM; Lange JM; Goudsmit J; Anderson RM; de Wolf F
AIDS; 2000 Apr; 14(6):659-69. PubMed ID: 10807189
[TBL] [Abstract][Full Text] [Related]
10. Modeling HIV-1 Latency Using Primary CD4
Takata H; Kessing C; Sy A; Lima N; Sciumbata J; Mori L; Jones RB; Chomont N; Michael NL; Valente S; Trautmann L
J Virol; 2019 Jun; 93(11):. PubMed ID: 30918072
[TBL] [Abstract][Full Text] [Related]
11. Human Galectin-9 Is a Potent Mediator of HIV Transcription and Reactivation.
Abdel-Mohsen M; Chavez L; Tandon R; Chew GM; Deng X; Danesh A; Keating S; Lanteri M; Samuels ML; Hoh R; Sacha JB; Norris PJ; Niki T; Shikuma CM; Hirashima M; Deeks SG; Ndhlovu LC; Pillai SK
PLoS Pathog; 2016 Jun; 12(6):e1005677. PubMed ID: 27253379
[TBL] [Abstract][Full Text] [Related]
12. Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1.
Kristoff J; Palma ML; Garcia-Bates TM; Shen C; Sluis-Cremer N; Gupta P; Rinaldo CR; Mailliard RB
EBioMedicine; 2019 May; 43():295-306. PubMed ID: 30952614
[TBL] [Abstract][Full Text] [Related]
13. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
14. Humanized Mouse Model of HIV-1 Latency with Enrichment of Latent Virus in PD-1
Llewellyn GN; Seclén E; Wietgrefe S; Liu S; Chateau M; Pei H; Perkey K; Marsden MD; Hinkley SJ; Paschon DE; Holmes MC; Zack JA; Louie SG; Haase AT; Cannon PM
J Virol; 2019 May; 93(10):. PubMed ID: 30842333
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Spontaneous Control of HIV-1 Is Related to Low Frequency of Infected Cells and Inefficient Viral Reactivation.
Noel N; Peña R; David A; Avettand-Fenoel V; Erkizia I; Jimenez E; Lecuroux C; Rouzioux C; Boufassa F; Pancino G; Venet A; Van Lint C; Martinez-Picado J; Lambotte O; Sáez-Cirión A; Prado JG
J Virol; 2016 Jul; 90(13):6148-6158. PubMed ID: 27122576
[TBL] [Abstract][Full Text] [Related]
16. Stimulating the RIG-I pathway to kill cells in the latent HIV reservoir following viral reactivation.
Li P; Kaiser P; Lampiris HW; Kim P; Yukl SA; Havlir DV; Greene WC; Wong JK
Nat Med; 2016 Jul; 22(7):807-11. PubMed ID: 27294875
[TBL] [Abstract][Full Text] [Related]
17. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
[TBL] [Abstract][Full Text] [Related]
18. Barriers to HIV Cure.
Stein J; Storcksdieck Genannt Bonsmann M; Streeck H
HLA; 2016 Oct; 88(4):155-63. PubMed ID: 27620852
[TBL] [Abstract][Full Text] [Related]
19. Higher expression of human telomerase reverse transcriptase in productively-infected CD4 cells possibly indicates a mechanism for persistence of the virus in HIV infection.
Suryawanshi P; Godbole S; Pawar J; Thakar M; Shete A
Microbiol Immunol; 2018 May; 62(5):317-326. PubMed ID: 29577368
[TBL] [Abstract][Full Text] [Related]
20. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
